ABOUT LIVEKIDNEY.BIO is a clinical stage biotech company developing a proprietary delivery platform, based on biodegradable hydrogel formulations for cell therapies. These medical moieties aim to prevent the progression of kidney disease towards kidney failure, as well as to improve related comorbidities such as diabetes, hypertension and obesity, thereby allowing kidney patients to live longer and healthier lives. Our solution could significantly alleviate the growing social burden and costs of kidney disease to patients and public healthcare organizations. GET IN TOUCH OUR PIPELINE: We develop proprietary pharma grade injectable hydrogel formulations to deliver Umbilical Cord–derived Mesenchymal Stromal Cells (UC-MSCs) to ameliorate the kidney function of advanced Chronic Kidney Disease (CKD) and Lupus Nephritis (LN) patients. Our pipeline offers a potentially safe and effective therapeutic path via a unique regional route of administration. In vitro studies > Animal studies > Clinical studies LK001 UC-MSC/ Subcutaneous ( Lupus Nephritis / CKD ) LK002 UC-MSC/ PRAT* ( Lupus Nephritis / CKD ) LK003 EVs / TBD ( CKD ) * Perirenal adipose tissue (PRAT) is a fat pad that surrounds the kidneys. PRAT functions: produce and release hormones and compounds which regulate renal and systemic metabolic functions. CKD MARKET Over 850 million (M) patients worldwide (WW), a devastating progressive disease with no cure Over 4M patients WW on dialysis with only one-third surviving 5 years >$130 billion annual expenses on CKD care in the US Patients reaching End-Stage Renal Disease (ESRD) are left with no cure and no hope There is an increasing unmet medical need for safe and effective treatments that can improve kidney function in advanced kidney disease patients before they require Renal Replacement Therapy (dialysis or transplantation) CKD MARKET Over 850 million (M) patients worldwide (WW), a devastating progressive disease with no cure Over 4M patients WW on dialysis with only one-third surviving 5 years >$130 billion annual expenses on CKD care in the US Patients reaching End-Stage Renal Disease (ESRD) are left with no cure and no hope There is an increasing unmet medical need for safe and effective treatments that can improve kidney function in advanced kidney disease patients before they require Renal Replacement Therapy (dialysis or transplantation) LUPUS NEPHRITIS MARKET Lupus Nephritis (LN) is a particularly severe kidney disease manifestation of Lupus, occurring in 60% of cases and correlating with a higher mortality rate. 5 million Lupus patients worldwide; chronic autoimmune disease in which the immune system attacks healthy tissues, causing inflammation and damage to various parts of the body, including the kidneys, skin, joints and other organs. Symptoms can vary widely and may include fatigue, joint pain, rashes, and kidney problems. Lupus predominantly affects women of childbearing age, with 10-fold higher prevalence in females. Lupus market is estimated around $1billion with an expected 5.6% annual growth rate. The main goal of LN management is to avoid ESRD.